Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn


4 points to note as resources rally

Andrew Fleming  |  13 Feb 2017Text size  Decrease  Increase  |  

Page 1 of 1

Schroders deputy head of Australian equities Andrew Fleming makes four observations on where he now sees value in the market.


Little more than a year ago, we were struck by how far materials, dominated by minerals producers, had fallen as a proportion of the ASX through time.

Just as commodity prices and, in turn, minerals producers' earnings oscillate, we felt valuation support justified a significant overweight to that sector even when commodity prices were at dire levels.

A year on and the ASX resources index has rallied 61 per cent, with the industrials index doing 6 per cent. Materials have reverted from 12 per cent of the market to 17 per cent; a move, however, only reflecting the earnings changes through that time, and not a rerating.

Multiples on material stocks are still low and, hence in the main, we still see more attractive valuation support for minerals producers, such as BHP Billiton (ASX: BHP), Rio Tinto (ASX: RIO), South32 (ASX: S32), Alumina (ASX: AWC) and Iluka Resources (ASX: ILU), than we do for the market as a whole.

In contrast, the big loser as a proportion of the market through the past year has been financials (including REITs), even though earnings have been relatively flat through that time.

Within that context, we would make four points on where we now see value. First, the market remains acutely sensitive to earnings revisions.

CSL Limited (ASX: CSL) increased by more than 10 per cent during the month, reflecting an earnings upgrade of 10 per cent, while Brambles (ASX: BXB) lost more than 15 per cent as earnings were decreased by 5 per cent.

This is especially the case where high multiples are the starting point, especially among mid and small caps.

Enter Aconex (ASX: ACX). Its share price fell 40 per cent during the month after the building-software company downgraded its outlook by a similar amount.

Given the company's operating cash flow is forecast to be less than $10 million this year, even with net revenue of $50 million, Aconex's market capitalisation of $600 million after the large correction, requires nothing short of large, sequential cash flow growth for many years to come.

The last year has highlighted to us, yet again, that picking inflection points in earnings momentum is precarious; who picked the commodity price rally from March last year? What was the catalyst?

It is why we continue to anchor to valuations in terms of portfolio positions, but nonetheless the power of revisions in market performance month to month is clear.

Second, while Aconex undoubtedly has a strong growth outlook and our concern rests with the multiple, it is a banner stock for a small companies index that continues to trade at a premium, for inferior earnings growth for industrial stocks.

The "illiquidity premium," which reached a zenith mid-2016, has unwound somewhat but may have further to go.

More rational than radical

Third, our portfolio positions are still overweight materials, especially miners, and underweight bond sensitives, reflecting valuations.

While both these positions are less pronounced than they were a year ago, their convergence has commenced but is still nascent, especially if bond yields continue to sell off--we use a 3 per cent bond rate as a midcycle proxy, slightly higher than the spot rate of 2.7 per cent (which was less than 2 per cent as recently as four months ago).

While the resources sector has moved from book value to 1.6 times book through the past year, defensive industrials continue to trade at a much higher multiple (2.7 times book), still 25 per cent above their long-run average.

Looked at another way, we still have 10 per cent-plus downside to our valuations for almost all REIT, healthcare and utility stocks; whereas we still have upside based on valuations for some of the resource names in our portfolio.

The valuation gap remains large but, of course, as it has narrowed through the past year so our portfolio tilts have converged as well.

Finally, while different from the norms of the past decade or more and, seeming to attract emotional responses, it appears at an objective level that many of the policies of US President Donald Trump are rational, albeit radical, in their implications for earnings for many ASX 200 stocks.

For example, allowing US states to block buy healthcare in order to exercise pricing power for "low-income citizens" appears to be economically and politically sensible and it remains mystifying why this hasn't happened already.

For ASX-listed companies exposed to the US healthcare market, this will provide a changed environment after many years of strong revenue growth as prices increased, while returns on capital started high and went higher.

Why is it rational for a US politician to preserve a system that sees US taxpayers and voters pay more for the same drugs than citizens of other countries such as Canada and Australia?

Maybe part of the equalisation of consumer prices globally sees prices in those markets increase and not just US prices decline. This will obviously affect many ASX-listed healthcare stocks but especially Mayne Pharma (ASX: MYX).

Encouragingly, US energy independence is also rational policy, albeit the promotion of the development of existing shale, oil and natural gas reserves will suppress energy prices globally.

Increasing infrastructure spending is also rational, especially to the extent that it is funded from savings in existing government expenditures. (Wastage in Pentagon outlays has already been highlighted.)

A proposed relaxation in US bank regulation has not just seen US banks stocks respond but has seen bank stocks rally globally through the past quarter, including in Australia.

Finally, if a protectionist agenda is pursued, given trade is about one-quarter of GDP for the US, about half of that of China and less than one-third that of Germany relative to GDP, the US may be hurt least from such a policy, notwithstanding all its attendant complications.

In all, a renewed focus by the US on fiscal policy, rather than the undue focus upon monetary policy, will have a material impact upon many sectors in the market and the pricing of assets (through increasing interest rates).

In some ways, to the extent the above policies are implemented, it is difficult to see them being wholly reversed by subsequent administrations. Hence, the impacts may be long lasting.

The "Trump rally" will not prove durable; assets are expensive, especially as interest rates normalise, and earnings growth is still weak.

However, the resetting of returns across the sectors detailed above that have otherwise had mostly stable experiences through the past 20 years will continue.

Investors are best to see current directions as an early warning signal, rather than a blip in a long-run trend.

More from Morningstar

• China crisis still a possibility

• What Trump's protectionism means for Australian investors


Andrew Fleming is deputy head of Australian equities at Schroders. This is a financial news article to be used for non-commercial purposes and is not intended to provide financial advice of any kind. Opinions expressed herein are subject to change without notice and may differ or be contrary to the opinions or recommendations of Morningstar as a result of using different assumptions and criteria.

© 2017 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.